[1]LI X,HE M,ZOU B.Value of miRNA-26a level in benign or malignant ascites[J].China Med Herald,2014,23(11):51-53,75.(in Chinese)李曦,何敏,邹兵.miRNA-26a在良、恶性腹水鉴别诊断中的意义[J].中国医药导报,2014,23(11):51-53,75.
|
[2] AKINCILAR SC,UNAL B,TERGAONKAR V.Reactivation of telomerase in cancer[J].Cell Mol Life Sci,2016,73(8):1659-1670.
|
[3]ZHANG Y,TOH L,LAU P,et al.Human telomerase reverse transcriptase(h TERT)is a novel target of the Wnt/β-catenin pathway in human cancer[J].J Biol Chem,2012,287(39):32494-32511.
|
[4]WANG JD,MA J,WANG FY,et al.Amplification of the telomeraes RNA component gene a new genetic marker for disease progression and prognosis in esophageal squamous cell carcinoma[J].Dis Esophagus,2013,26(7):737-745.
|
[5]WELLENHOFER A,BRUSTMANN H.Expression of human telomerase reverse transcriptase in vulvar intraepithelial neoplasia and squamous cell carcinoma:an immunohistochemical study with survivin and p53[J].Arch Pathol Lab Med,2012,136(11):1359-1365.
|
[6]MOCELIN S,POOLEY KA,NITTI D,et al.Telomerase and the search for the end of cancer[J].Trends Mol Med,2013,19(2):125-133.
|
[7]BERNARDES de JESUS B,BLASCO MA.Telomerase at the intersection of cancer and aging[J].Trends Genet,2013,29(9):513-520.
|
[8]PARK ES,LEE J,KANG SY,et al.A comparative study of telomerase activity and cytologic diagnosis in malignant ascites[J].Ana Quant Cytopathol Histpathol,2013,35(3):146-151.
|
[9]CAO M,YIE SM,LIU J,et al.Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal,gastric,esophagea and lung cancer[J].Tissue Antigens,2011,78(2):120-128.
|
[10]PARK GM,LEE S,PARK B,et al.Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis[J].Biochem Biophys Res Commun,2004,313(3):606-611.
|
[11]YAN WH.HLA-G expression in cancers:potential role in diagnosis,prognosis and therpy[J].Endocr Metab Immune Disord Drug Targets,2011,11(1):76-89.
|
[12]YAN WH.Human leukocyte antigen-G in cancer:are they clinically relevant?[J].Cancer Lett,2011,311(2):123-130.
|
[13]YIE SM,HU Z.Human leukocyte antigen-G(HLA-G)as a marker for diagnosis,prognosis and tumor immue escape in human malignancies[J].Histol Histopathol,2011,26(3):409-420.
|
[14]OTROCK ZK,MAKAREM JA,SHAMSEDDINE AI,et al.Vascular endothelial growth factor family of ligands and receptors:review[J].Blood Cells Mol Dis,2007,38(3):258-268.
|
[15]COSMAI L,GALLIENI M,LIGUIGLI W,et al.Renal toxicity of anticancer agents targeting vascular endothelial growth factor(VEGF)and its receptors(VEGFRs)[J].J Nephrol,2016.[Epub ahead of print]
|
[16]KERAMOCHI H,HAYASHI K,UCHIDA K,et al.Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer[J].Clin Cancer Res,2006,12(1):29-33.
|
[17]ZHAN N,DONG WG,WANG J.The clinical significance of vascular endothelial growth factor in malignant ascites[J].Tumour Biol,2016,37(3):3719-3725.
|
[18]LYU XG,DONG WG,ZHAN N,et al.Diagnostic value of vascular endothelial growth factor in differentiation of malignant ascites:a meta-analysis[J].Chin J Evid-Based Med,2011,11(2):220-225.(in Chinese)吕晓光,董卫国,詹娜,等.血管内皮生长因子对恶性腹腔积液诊断价值的meta分析[J].中国循证医学杂志,2011,11(2):220-225.
|
[19]WEI H,QIN S,YIN X,et al.Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites[J].Oncol Lett,2015,9(6):2694-2700.
|
[20]NOH S,JUNG JJ,JUNG M,et al.Body fluid MMP-2 as a putative biomarker in metastatic breast cancer[J].Oncol Lett,2012,3(3):699-703.
|
[21]NOH S,JUNG JJ,JUNG M,et al.MMP-2 as a putative biomarker for carcinomatosis in gastric cancer[J].Hepatogastroenterology,2011,58(112):2015-2019.
|
[22]NESI G,BRUNO L,SAIEVA C,et al.DNA ploidy and S-phase fraction as prognostic factors in surgically resected gastric carcinoma:a 7-year prospective study[J].Anticancer Res,2007,27(6C):4435-4441.
|
[23]ZHANG L,WANG Q,LI F,et al.Meta-analysis on the diagnostic value of DNA aneuploid for malignant ascites[J].Shandong Med J,2010,50(43):37-39.(in Chinese)张垒,王强,李富,等.DNA异倍体检测对恶性腹水诊断价值的Meta分析[J].山东医药,2010,50(43):37-39.
|
[24] GILL M,SINGH U,MAHAATRA QS,et al.Role of argyrophilic nucleolar organizer region staining in identification of malignant cells in effusion[J].J Cytol,2011,28(4):191-195.
|
[25]ROCHER AE,GUERRA F,ROFRANO J,et al.Sensitivity and specificity of cytodiagnosis of body fluids in a laboratory of urgencies[J].Biotech Histochem,2011,86(5):326-332.
|
[26]ZHU FL,LING AS,WEI Q,et al.Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites[J].Asian Pac J Cancer Prev,2015,16(2):719-722.
|
[27]LIU F,KONG XJ,DOU Q,et al.Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites[J].Ann Hepatol,2014,13(3):357-363.
|
[28] PAVITHRA V,SATHISHA TG,KASTURI K,et al.Serum levels of metal ions in femal patients with breast cancer[J].J Clin Diagn Res,2015,9(1):25-27.
|
[29] KABA M,PIRINCCI N,YUKSEL MB,et al.Serum levels of trace elements in patients with prostate cancer[J].Asian Pac J Cancer Prev,2014,15(6):2625-2629.
|
[30]SHETTY SR,BABU S,KUMARI S,et al.Status of trace elements in saliva of oral precancer and oral cancer patients[J].J Cancer Res Ther,2015,11(1):146-149.
|
[31]CHEN H,TAN C,WU T.Ensemble modeling coupled with six element concentrations in human blood for cancer diagnosis[J].Biol Trace Elem Res,2011,143(1):143-152
|
[32]KIM ES,LIM CS,CHUN HJ,et al.Detection of Cu(Ⅰ)and Zn(Ⅱ)ions in colon neoplasm[J].J Clin Pathol,2012,65(10):882-887.
|
[33]DING R,JIA JD.Progress in evaluation and treatment of hepatic iron overload[J].J Clin Hepatol,2014,30(9):961-964.(in Chinese)丁蕊,贾继东.肝脏铁过载的评估及治疗新进展[J].临床肝胆病杂志,2014,30(9):961-964.
|
[34] UCHINO K,TATEISHI R,FUJIWARA N,et al.Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients[J].Hepatol Res,2016,46(4):259-268.
|
[35]JI M,LI XD,SHI HB,et al.Clinical significance of serum ferritin in elderly patients with primary lung carcinoma[J].Tumour Biol,2014,35(10):10195-10199.
|
[36] CHEKHUN SV,LUKYANOVA NY,SHVETS YV,et al.Significance of ferritin expression in formation of malignant phenotype of human breast cancer cells[J].Exp Oncol,2014,36(3):179-183.
|
[37]KUCUKGOZ GULEC U,PAYDAS S,GUZEL AB,et al.Comparative analysis of CA-125,ferritin,beta-2 microglobulin,lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia[J].Med Oncol,2012,29(4):2937-2943.
|
[38]ALKHATEEB A,ZUBRITSKY L,KINSMAN B,et al.Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease[J].J Gastrointest Cancer,2014,45(2):161-167.
|
[39]WU J,WANG HL.Clinical significance of tumor markers of tumor ferritin,CA125 combined detection in benign and malignant ascites’s differential diagnosis[J].China J Modern Med,2014,24(36):35-38.(in Chinese)吴江,汪宏良.铁蛋白与CA125联合检测在良、恶性腹水鉴别诊断中的临床意义[J].中国现代医学杂志,2014,24(36):35-38.
|
[40]YUAN K,KUCIK D,SINGH RK,et al.Alterations in human breast cancer adhesion-motility in response to changes in cell surface glycoproteins displaying alpha-L-fucose moieties[J].Int JOncol,2008,32(4):797-807.
|
[41]MOSSAD NA,MAHMOUD EH,OSMAN EA,et al.Evaluation of squamous cell carcinoma natigen-immunoglobulin M complex(SC-CA-IGM)and alpha-L-fucosidase(AFU)as novel diagnostic biomarkers for hepatocellular carcinoma[J].Tumor Biol,2014,35(11):11559-11564.
|
[42]FAWZY MONTASER M,AMIN SAKR M,OMAR KHALIFA M.Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma[J].Arab J Gastroenterol,2012,13(1):9-13.
|
[43]WANG K,GUO W,LI N,et al.Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following he patectomy:a large-scale,long-term study[J].Br J Cancer,2014,110(7):1811-1819.
|
[44]SU SB,QIN SY,GUO XY,et al.Assessment by meta-analysis of interferon-gamma for the diagnosis of tuberculous peritonitis[J].World J Gastroenterol,2013,19(10):1645-1651.
|
[45]TAO L,NING HJ,NIE HM,et al.Diagnostic value of adenosine deaminase in ascites for tuberculosis ascites:a meta-analysis[J].Diagn Microbiol Infect Dis,2014,79(1):102-107.
|
[46]WALIA A,YANG JF,HUANG YH,et al.Endostatin’s emerging roles in angiogenesis,lymphangiogenesis,disease,and clinical applications[J].Biochim Biophys Acta,2015,1850(12):2422-2438.
|
[47]CHENG D,LIANG B,KONG H,et al.Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites[J].Med Oncol,2012,29(2):1397-1402.
|
[48] WEI H,QIN S,YIN X,et al.Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites[J].Oncol Lett,2015,9(6):2694-2700.
|
[49]WU CY,WANG W,CHEN X,et al.Efficacy of recombinant human endostatin in treatment of malignant peritoneal effusion in mice and its mechanisms of action[J].Chin J Clin Pharmacol Ther,2014,19(5):507-511.(in Chinese)吴春艳,王伟,陈鑫,等.重组人血管内皮抑素治疗小鼠恶性腹腔积液疗效及作用机制研究[J].中国临床药理学与治疗学,2014,19(5):507-511.
|
[50]PEDRAZZANI C,CARUSO S,CORSO G,et al.Influence of age on soluble E-cadherin serum levels prevents its utility as a disease marker in gastric cancer patients[J].Stand J Gastroenterol,2008,43(6):765-766.
|
[51]MOGHADDAM NA,TAHRIRIAN R,EFTEKHARI M,et al.Diagnostic value of E-cadherin and fibronectin in differentiation between reactive mesothelial and adenocarcinoma cells in serous effusions[J].Adv Biomed Res,2012,1:56
|